• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5071034)   Today's Articles (71)
For: Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Teprotumumab Efficacy, Safety and Durability in Longer Duration Thyroid Eye Disease and Retreatment: Optic-X Study. Ophthalmology 2021;129:438-449. [PMID: 34688699 DOI: 10.1016/j.ophtha.2021.10.017] [Citation(s) in RCA: 88] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2021] [Revised: 10/12/2021] [Accepted: 10/15/2021] [Indexed: 02/06/2023]  Open
Number Cited by Other Article(s)
1
Abumohssin AG, Alshareef RA, Aljohani S, Alqutub A, Alqutub A. Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves' orbitopathy: a systematic review and meta-analysis. Eye (Lond) 2025:10.1038/s41433-025-03845-8. [PMID: 40404973 DOI: 10.1038/s41433-025-03845-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2024] [Revised: 04/14/2025] [Accepted: 05/07/2025] [Indexed: 05/24/2025]  Open
2
Lo JE, Freitag SK, Liu CY, Barbesino G, Sheng-Kai Ma K. Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease: A Target Trial Emulation. Ophthalmology 2025:S0161-6420(25)00310-0. [PMID: 40398692 DOI: 10.1016/j.ophtha.2025.05.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2024] [Revised: 05/08/2025] [Accepted: 05/13/2025] [Indexed: 05/23/2025]  Open
3
Rowe LW, Barry ZR, Mackay DD, Lai KE, Ciulla TA. Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies. Expert Opin Biol Ther 2025;25:1-22. [PMID: 40298278 DOI: 10.1080/14712598.2025.2491603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2025] [Revised: 04/01/2025] [Accepted: 04/07/2025] [Indexed: 04/30/2025]
4
Huang W, Ou X, Lin S, Lin W, Chen G, Huang H, Wen J. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis. Endocr Pract 2025;31:640-649. [PMID: 39952471 DOI: 10.1016/j.eprac.2025.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2024] [Revised: 12/30/2024] [Accepted: 01/29/2025] [Indexed: 02/17/2025]
5
Roztocil E, Husain F, Patrick CC, Feldon SE, Woeller CF. Targeting the Aryl Hydrocarbon Receptor to Attenuate IGF1R Signaling in Thyroid Eye Disease. Thyroid 2025;35:527-542. [PMID: 40257057 DOI: 10.1089/thy.2024.0529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/22/2025]
6
Walsh HL, Clauss KD, Meyer BI, Parunakian E, Yasar C, Chiou CA, Johnson TE, Ugradar S, Kossler AL, Freitag SK, Douglas RS, Wester ST. Surgical Timing for Patients With Thyroid Eye Disease Treated With Teprotumumab: A Collaborative Multicenter Study. Ophthalmic Plast Reconstr Surg 2025;41:320-328. [PMID: 39656059 DOI: 10.1097/iop.0000000000002839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2025]
7
Lin S, Ou X, Cai L, Huang W, Wen J. Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis. J Endocrinol Invest 2025:10.1007/s40618-025-02595-4. [PMID: 40304985 DOI: 10.1007/s40618-025-02595-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2025] [Accepted: 04/19/2025] [Indexed: 05/02/2025]
8
Gorelik D, Mehdi Z, Khan NS, Majeethia H, Takashima M, Lu T, Malik A, Ahmed OG. Orbital Decompression in the Biologic Era: Is There Still a Need for Surgery? Int Forum Allergy Rhinol 2025:e3603. [PMID: 40299895 DOI: 10.1002/alr.23603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2024] [Revised: 03/25/2025] [Accepted: 04/18/2025] [Indexed: 05/01/2025]
9
Markle JC, Johanis A, Shaia JK, Benito D, Talcott KE, Singh RP. Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis. Eye (Lond) 2025;39:1107-1114. [PMID: 39668181 PMCID: PMC11978748 DOI: 10.1038/s41433-024-03531-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 11/12/2024] [Accepted: 11/29/2024] [Indexed: 12/14/2024]  Open
10
Lanzolla G, Rotondo Dottore G, Comi S, Cosentino G, Ciampa DA, Sabini E, Menconi F, Maglionico MN, Posarelli C, Rocchi R, Latrofa F, Figus M, Santini F, Marinò M. In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy. Endocrine 2025:10.1007/s12020-025-04219-6. [PMID: 40156685 DOI: 10.1007/s12020-025-04219-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2025] [Accepted: 03/17/2025] [Indexed: 04/01/2025]
11
Lee ACH, Kahaly GJ. Targeted immunotherapies for Graves' thyroidal & orbital diseases. Front Immunol 2025;16:1571427. [PMID: 40145088 PMCID: PMC11936961 DOI: 10.3389/fimmu.2025.1571427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2025] [Accepted: 02/21/2025] [Indexed: 03/28/2025]  Open
12
Smith TJ. Controversies Surrounding IGF-I Receptor Involvement in Thyroid-Associated Ophthalmopathy. Thyroid 2025;35:232-244. [PMID: 39909461 DOI: 10.1089/thy.2024.0606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2025]
13
Smith TJ, Holt RJ, Fu Q, Qashqai A, Barretto N, Conrad E, Brant JA. Assessment of Hearing Dysfunction in Patients With Graves' Disease and Thyroid Eye Disease Without or With Teprotumumab. J Clin Endocrinol Metab 2025;110:811-819. [PMID: 39138817 PMCID: PMC11834702 DOI: 10.1210/clinem/dgae560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2024] [Revised: 08/08/2024] [Accepted: 08/12/2024] [Indexed: 08/15/2024]
14
Li Z. Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy. Front Endocrinol (Lausanne) 2025;15:1469268. [PMID: 39872310 PMCID: PMC11769798 DOI: 10.3389/fendo.2024.1469268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2024] [Accepted: 12/23/2024] [Indexed: 01/30/2025]  Open
15
Chen Y, Linaburg T, Wang S, Merchant G, Pradeep T, Augello PA, Ying GS, Briceño CA, Tamhankar MA. Observational Characterization of the Retreatment Course of Patients With Thyroid Eye Disease. J Neuroophthalmol 2025:00041327-990000000-00757. [PMID: 39780310 DOI: 10.1097/wno.0000000000002280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2025]
16
Al-Sharif EM, Zhou J, Shoji MK, Acuff K, Liu CY, Korn BS, Kikkawa DO. Effects of Teprotumumab on Eyelid Retraction in Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg 2025;41:22-27. [PMID: 38722772 DOI: 10.1097/iop.0000000000002707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2025]
17
Huang J, Su A, Yang J, Zhuang W, Li Z. Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment. J Clin Endocrinol Metab 2024;110:159-165. [PMID: 38878281 PMCID: PMC11651674 DOI: 10.1210/clinem/dgae417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Indexed: 12/19/2024]
18
Davis JB, Mudalegundi S, Henderson AD, Carey AR. Stability of Ocular Alignment After Teprotumumab Therapy in a Cohort of Patients With Thyroid Eye Disease and Baseline Diplopia. J Neuroophthalmol 2024;44:527-532. [PMID: 38170616 DOI: 10.1097/wno.0000000000002066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
19
Chen Y, Qi X, Wang J, Xu H, Sun Y, Wang L, Zhou X, He M, Zhao J, Zhang J, He H, Guo H, Shi B, Wang Y, Zhang M. Hyperlipidemia and apolipoprotein E are associated with intraocular pressure of thyroid-associated ophthalmopathy in a Chinese population: a cross-sectional study. Front Endocrinol (Lausanne) 2024;15:1484343. [PMID: 39669501 PMCID: PMC11634611 DOI: 10.3389/fendo.2024.1484343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2024] [Accepted: 11/05/2024] [Indexed: 12/14/2024]  Open
20
Wang M, Liu L. Advances of IGF-1R inhibitors in Graves' ophthalmopathy. Int Ophthalmol 2024;44:435. [PMID: 39578269 DOI: 10.1007/s10792-024-03358-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 11/08/2024] [Indexed: 11/24/2024]
21
Lanzolla G, Marinò M, Menconi F. Graves disease: latest understanding of pathogenesis and treatment options. Nat Rev Endocrinol 2024;20:647-660. [PMID: 39039206 DOI: 10.1038/s41574-024-01016-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/20/2024] [Indexed: 07/24/2024]
22
Hoang TD, Flor RJ, De La Torre S, Nguyen C, Raiciulescu S, Shakir MKM, Chou E. Effects of Teprotumumab and Role of Human Leukocyte Antigens Markers in Patients With Thyroid Eye Disease. Endocr Pract 2024;30:1038-1043. [PMID: 39187158 DOI: 10.1016/j.eprac.2024.08.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2024] [Revised: 08/11/2024] [Accepted: 08/20/2024] [Indexed: 08/28/2024]
23
Kulbay M, Tanya SM, Tuli N, Dahoud J, Dahoud A, Alsaleh F, Arthurs B, El-Hadad C. A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches. Int J Mol Sci 2024;25:11628. [PMID: 39519180 PMCID: PMC11546489 DOI: 10.3390/ijms252111628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2024] [Revised: 10/21/2024] [Accepted: 10/25/2024] [Indexed: 11/16/2024]  Open
24
Rachmasari KN, Toro-Tobon D, Wagner LH, Tooley AA, Bradley EA, Stan MN. Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease. Endocr Pract 2024;30:937-942. [PMID: 38936546 DOI: 10.1016/j.eprac.2024.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2024] [Revised: 06/17/2024] [Accepted: 06/20/2024] [Indexed: 06/29/2024]
25
Householder NA, Ray C. Teprotumumab's Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis. TOUCHREVIEWS IN ENDOCRINOLOGY 2024;20:100-109. [PMID: 39526058 PMCID: PMC11548351 DOI: 10.17925/ee.2024.20.2.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Accepted: 08/20/2024] [Indexed: 11/16/2024]
26
Martel A, Rocher F, Gerard A. Teprotumumab for the Treatment of Thyroid Eye Disease: Why Should We Keep Our Eyes "Wide Open"?-A Clinical and Pharmacovigilance Point of View. J Pers Med 2024;14:1027. [PMID: 39452535 PMCID: PMC11508897 DOI: 10.3390/jpm14101027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2024] [Revised: 09/22/2024] [Accepted: 09/24/2024] [Indexed: 10/26/2024]  Open
27
Rosenblatt TR, Chiou CA, Yoon MK, Wolkow N, Lee NG, Freitag SK. Reply Re: "Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease". Ophthalmic Plast Reconstr Surg 2024;40:583. [PMID: 39240200 DOI: 10.1097/iop.0000000000002786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/07/2024]
28
Dosiou C. Teprotumumab for Inactive Thyroid Eye Disease? The Jury Is Still Out. J Clin Endocrinol Metab 2024;109:e1802-e1803. [PMID: 38279938 DOI: 10.1210/clinem/dgae052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 01/19/2024] [Accepted: 01/23/2024] [Indexed: 01/29/2024]
29
Zhang C, Ersan S, Yousef Y, Sandhur B, Desilets J, McGlone C, Kellner T, Teru S, Reynolds AL. The effect of teprotumumab infusion on ocular alignment in patients with symptomatic thyroid eye disease. J AAPOS 2024;28:103959. [PMID: 38944235 DOI: 10.1016/j.jaapos.2024.103959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 03/26/2024] [Accepted: 03/29/2024] [Indexed: 07/01/2024]
30
Scarabosio A, Surico PL, Singh RB, Tereshenko V, Musa M, D’Esposito F, Russo A, Longo A, Gagliano C, Agosti E, Jhanji E, Zeppieri M. Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management. J Pers Med 2024;14:776. [PMID: 39064030 PMCID: PMC11278049 DOI: 10.3390/jpm14070776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2024] [Revised: 07/16/2024] [Accepted: 07/18/2024] [Indexed: 07/28/2024]  Open
31
Smith TJ, Cavida D, Hsu K, Kim S, Fu Q, Barbesino G, Wester ST, Holt RJ, Bhattacharya RK. Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials. Ophthalmology 2024;131:815-826. [PMID: 38253291 DOI: 10.1016/j.ophtha.2024.01.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 01/12/2024] [Accepted: 01/16/2024] [Indexed: 01/24/2024]  Open
32
Dallalzadeh LO, Villatoro GA, Chen L, Sim MS, Movaghar M, Robbins SL, Karlin JN, Khitri MR, Velez FG, Korn BS, Demer JL, Rootman DB, Granet DB, Kikkawa DO. Teprotumumab for Thyroid Eye Disease-related Strabismus. Ophthalmic Plast Reconstr Surg 2024;40:434-439. [PMID: 38319994 PMCID: PMC11718340 DOI: 10.1097/iop.0000000000002611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2024]
33
Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. Thyroid 2024;34:880-889. [PMID: 38824618 DOI: 10.1089/thy.2023.0656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/04/2024]
34
Hwang CJ, Rebollo NP, Mechels KB, Perry JD. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease. Am J Ophthalmol 2024;263:152-159. [PMID: 38142982 DOI: 10.1016/j.ajo.2023.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Revised: 11/30/2023] [Accepted: 12/01/2023] [Indexed: 12/26/2023]
35
Moledina M, Damato EM, Lee V. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye (Lond) 2024;38:1425-1437. [PMID: 38374366 PMCID: PMC11126416 DOI: 10.1038/s41433-024-02967-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Revised: 01/07/2024] [Accepted: 01/26/2024] [Indexed: 02/21/2024]  Open
36
Hilliard G, Pruett J, Donahue SP, Velez FG, Peragallo JH, Ditta LC, Tavakoli M, Hoehn ME, Kuo AF, Indaram M, Kerr NC. Outcomes of Strabismus Surgery Following Teprotumumab Therapy. Am J Ophthalmol 2024;262:186-191. [PMID: 38191066 DOI: 10.1016/j.ajo.2024.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 12/27/2023] [Accepted: 01/03/2024] [Indexed: 01/10/2024]
37
Eckstein A, Welkoborsky HJ. [Interdisciplinary Management of Orbital Diseases]. Laryngorhinootologie 2024;103:S43-S99. [PMID: 38697143 DOI: 10.1055/a-2216-8879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2024]
38
Qi L, Song X, Li Y, Sun J, Zhou H, Fan X. Predictive model for the progression of inactive thyroid eye disease: a retrospective study. Endocrine 2024;84:533-540. [PMID: 37936006 DOI: 10.1007/s12020-023-03582-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Accepted: 10/18/2023] [Indexed: 11/09/2023]
39
Men CJ, Amarikwa L, Pham B, Sears C, Clauss K, Lee BW, Lee WW, Pasol J, Ugradar S, Shinder R, Cockerham K, Wester S, Douglas R, Kossler AL. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg 2024;40:276-285. [PMID: 37972960 PMCID: PMC11090759 DOI: 10.1097/iop.0000000000002564] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
40
Ting MAJ, Topilow NJ, Ediriwickrema LS, Yoon JS, Liu CY, Korn BS, Kikkawa DO. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease. Orbit 2024;43:222-230. [PMID: 37978819 DOI: 10.1080/01676830.2023.2282509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 11/07/2023] [Indexed: 11/19/2023]
41
Zhang S, Wang Y, Qi Z, Tong S, Zhu D. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database. Int J Clin Pharm 2024;46:471-479. [PMID: 38245664 DOI: 10.1007/s11096-023-01676-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Accepted: 11/20/2023] [Indexed: 01/22/2024]
42
Mudalegundi S, Huang P, Henderson AD, Carey AR. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease. J Neuroophthalmol 2024;44:80-86. [PMID: 38294416 DOI: 10.1097/wno.0000000000002001] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
43
Rosenblatt TR, Chiou CA, Yoon MK, Wolkow N, Lee NG, Freitag SK. Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg 2024;40:187-191. [PMID: 37791840 DOI: 10.1097/iop.0000000000002531] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/05/2023]
44
North VS, Dolman PJ, Garrity JA, Kazim M. Disease Modulation Versus Modification: A Call for Revised Outcome Metrics in the Treatment of Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg 2024;40:156-160. [PMID: 38285956 DOI: 10.1097/iop.0000000000002591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2024]
45
Carter C, Marks M, Bundeff AW, Adewodu T, Alderman L. A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease. Endocrine 2024;83:65-68. [PMID: 37725291 DOI: 10.1007/s12020-023-03531-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 09/03/2023] [Indexed: 09/21/2023]
46
Eckstein A, Stöhr M, Görtz GE, Gulbins A, Möller L, Fuehrer-Sakel D, Oeverhaus M. Current Therapeutic Approaches for Graves' Orbitopathy - are Targeted Therapies the Future? Klin Monbl Augenheilkd 2024;241:48-68. [PMID: 37799096 DOI: 10.1055/a-2186-5548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023]
47
Mehta P, Angell T, LeTran V, Lin M, Nguyen A, Zhang-Nunes S. Long-Term Follow-Up of a Case of Severe Hyperglycemia Requiring Hospitalization after Third Dose of Teprotumumab: A Case Report. Case Rep Ophthalmol 2024;15:115-121. [PMID: 38318283 PMCID: PMC10843176 DOI: 10.1159/000536153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2023] [Accepted: 01/02/2024] [Indexed: 02/07/2024]  Open
48
Sharma Y, Patel P, Kurmi BD. A Mini-review on New Developments in Nanocarriers and Polymers for Ophthalmic Drug Delivery Strategies. Curr Drug Deliv 2024;21:488-508. [PMID: 37143264 DOI: 10.2174/1567201820666230504115446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 02/20/2023] [Accepted: 03/13/2023] [Indexed: 05/06/2023]
49
Goldberg H, Malik AI. Teprotumumab in thyroid eye disease. Saudi J Ophthalmol 2024;38:29-33. [PMID: 38628412 PMCID: PMC11017013 DOI: 10.4103/sjopt.sjopt_179_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 11/30/2023] [Accepted: 12/12/2023] [Indexed: 04/19/2024]  Open
50
Cieplińska K, Niedziela E, Kowalska A. Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets. J Clin Med 2023;13:72. [PMID: 38202079 PMCID: PMC10780108 DOI: 10.3390/jcm13010072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 12/17/2023] [Accepted: 12/20/2023] [Indexed: 01/12/2024]  Open
PrevPage 1 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA